Safety and tolerability of PCSK9i and ANGPTL3i in HoFH patients
At the end of the follow-up period, no significant difference was observed between the groups with regards to the prevalence of TEAE or treatment discontinuation (p > 0.05 for both). The prevalence of gastroenteritis, abdominal pain, nausea, and vomiting was higher, while injection site reactions, upper respiratory tract infections, and elevated creatine kinase were less prevalent in the ANGPTL3i group compared to PCSK9i (p > 0.05 for all). Other adverse clinical events were not significantly different between the groups (Table 2 ).